You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科濟藥業(02171.HK)公佈候選產品最新試驗進展
阿思達克 09-20 09:03
科濟藥業(02171.HK)公佈,公司已於2021年歐洲腫瘤內科學會大會以口頭報告形式呈列發佈CT041(一種靶向CLDN18.2自體CAR-T候選產品)研究者發起的試驗進展。 CT041是一種潛在全球同類首創的、靶向CLDN18.2自體CAR-T候選產品,經開發用於治療CLDN18.2陽性實體瘤,主要治療胃癌╱胃食管結合部癌及胰腺癌。CT041總體耐受性良好。未發生治療相關死亡或免疫細胞治療相關神經系統毒性綜合徵(ICANS)。約95%的患者發生CRS,所有CRS均爲1級或2級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account